SENTINEL LIFE researches and develops advanced biomaterials for the regeneration of autologous tissue. The combination of tissue-specific biomaterials with suitable surgical methods open up innovative treatment concepts of regenerative medicine. The aim is the testing and approval of these biomaterials for clinical use, and the opening of new therapies for patients.
Research and development is based on the latest scientific findings. Researchers from the university hospital Klinikum rechts der Isar of the Technical University of Munich and researchers from the Queensland University of Technology (Australia) combine state-of-the-art medicine with latest technology.
Regeneration of lymphatic tissue
The research is focused mainly on the development of biomaterials for the regeneration of lymphatic tissue. The combination of advanced biomaterials with suitable surgical methods is supposed to provide a causal treatment method of chronic lymphedema. Chronic lymphedema is caused by an insufficient lymphatic system and is manifested by lifelong swelling of the arms or legs. The treatment method of SENTINEL LIFE is meant to be a causal therapy, which replaces the conventional transplantation of lymph nodes.
Please note that the procedure of SENTINEL LIFE is still in a research stage. First patients are expected to be treated within a clinical trial in the year 2018. If you are interested in current research developments or in participating in a clinical trial, please leave your contact details here.